| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Autolus Therapeutics plc
13D/A
AUTL · 05280R100
|
7.6% |
11/10/2026
Event 11/6/2026
|
||||
| BXLS V - Autobahn L.P. | 7.6% | |||||
| Blackstone Life Sciences Associates V (CYM) L.L.C. | 7.6% | |||||
| BXLS V L.L.C. | 7.6% | |||||
| Blackstone Holdings II L.P. | 7.6% | |||||
| Blackstone Holdings I/II GP L.L.C. | 7.6% | |||||
| Blackstone Inc. | 7.6% | |||||
| Blackstone Group Management L.L.C. | 7.6% | |||||
| Stephen A. Schwarzman | 7.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.